NASDAQ:AADI Aadi Bioscience - AADI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.75 +0.16 (+2.11%) (As of 03/21/2023 12:48 PM ET) Add Compare Share Share Today's Range$7.51▼$7.7650-Day Range$7.40▼$13.0052-Week Range$7.00▼$18.68Volume49,300 shsAverage Volume126,070 shsMarket Capitalization$189.10 millionP/E RatioN/ADividend YieldN/APrice Target$41.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Aadi Bioscience MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside451.1% Upside$41.67 Price TargetShort InterestBearish7.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.70) to ($2.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.93 out of 5 starsMedical Sector644th out of 988 stocksPharmaceutical Preparations Industry307th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingAadi Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.67, Aadi Bioscience has a forecasted upside of 451.1% from its current price of $7.56.Amount of Analyst CoverageAadi Bioscience has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.33% of the float of Aadi Bioscience has been sold short.Short Interest Ratio / Days to CoverAadi Bioscience has a short interest ratio ("days to cover") of 11.3, which indicates bearish sentiment.Change versus previous monthShort interest in Aadi Bioscience has recently increased by 6.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAadi Bioscience does not currently pay a dividend.Dividend GrowthAadi Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AADI. Previous Next 2.3 News and Social Media Coverage News SentimentAadi Bioscience has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aadi Bioscience this week, compared to 1 article on an average week.Search Interest11 people have searched for AADI on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aadi Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders31.80% of the stock of Aadi Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.09% of the stock of Aadi Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aadi Bioscience are expected to grow in the coming year, from ($2.70) to ($2.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aadi Bioscience is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aadi Bioscience is -2.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAadi Bioscience has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aadi Bioscience (NASDAQ:AADI) StockAadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.Read More Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address AADI Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comAadi Bioscience, Inc. (NASDAQ:AADI) Short Interest UpdateMarch 15, 2023 | finance.yahoo.comAadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate UpdateMarch 21, 2023 | Upexi, Inc (Ad)The 1 Stock To Watch In This Market.This NASDAQ Stock Has Been On The Move In 2023 And It Looks Like Its Far From Over!March 14, 2023 | americanbankingnews.comAadi Bioscience (AADI) Scheduled to Post Quarterly Earnings on WednesdayMarch 3, 2023 | marketwatch.comAadi Bioscience President, CEO Brendan Delaney Resigns >AADIMarch 3, 2023 | marketwatch.comAadi Bioscience Shares Touch 52-Week Low as CEO Delaney Resigns >AADIMarch 3, 2023 | finance.yahoo.comAadi Bioscience Announces Leadership TransitionFebruary 22, 2023 | finance.yahoo.comAadi Bioscience to Present at the 43rd Annual Cowen Healthcare ConferenceMarch 21, 2023 | Press Research (Ad)Stocks For Smart InvestorsThis under-the-radar stock is in the right industry at the perfect time.February 7, 2023 | finance.yahoo.comShareholders in Aadi Bioscience (NASDAQ:AADI) are in the red if they invested a year agoJanuary 11, 2023 | finance.yahoo.comOwning 41% shares,institutional owners seem interested in Aadi Bioscience, Inc. (NASDAQ:AADI),January 6, 2023 | msn.comAadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?November 17, 2022 | finance.yahoo.comAadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual MeetingNovember 12, 2022 | finance.yahoo.comAnalysts Are Upgrading Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest ResultsNovember 11, 2022 | uk.finance.yahoo.comAadi Bioscience Third Quarter 2022 Earnings: Beats ExpectationsNovember 9, 2022 | seekingalpha.comAadi Bioscience, Inc. (AADI) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | msn.comAadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue EstimatesNovember 9, 2022 | finance.yahoo.comAadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate UpdateNovember 8, 2022 | finance.yahoo.comAadi Bioscience Announces Planned Leadership TransitionNovember 3, 2022 | finance.yahoo.comAadi Bioscience to Present at Upcoming Investor ConferencesNovember 2, 2022 | markets.businessinsider.comAadi Bioscience to Report Third Quarter 2022 Results and Corporate UpdateOctober 17, 2022 | finance.yahoo.comWe're Keeping An Eye On Aadi Bioscience's (NASDAQ:AADI) Cash Burn RateOctober 12, 2022 | finance.yahoo.comMirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] MutationOctober 12, 2022 | finance.yahoo.comAadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR SymposiumOctober 4, 2022 | nasdaq.comAadi Bioscience (NASDAQ:AADI) one-year losses have grown faster than shareholder returns have fallen, but the stock soars 12% this past weekSeptember 22, 2022 | finance.yahoo.comAadi Bioscience Announces $72.5 Million Private Placement Equity FinancingSeptember 16, 2022 | finance.yahoo.comIs Aadi Bioscience, Inc. (NASDAQ:AADI) Trading At A 29% Discount?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address AADI Company Calendar Last Earnings8/10/2021Today3/21/2023Next Earnings (Confirmed)3/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AADI CUSIPN/A CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.67 High Stock Price Forecast$48.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+449.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,090,000.00 Net Margins-569.57% Pretax Margin-569.49% Return on Equity-44.28% Return on Assets-38.30% Debt Debt-to-Equity RatioN/A Current Ratio10.61 Quick Ratio10.57 Sales & Book Value Annual Sales$1.12 million Price / Sales165.35 Cash Flow$1.84 per share Price / Cash Flow4.12 Book Value$6.53 per share Price / Book1.16Miscellaneous Outstanding Shares24,400,000Free Float16,637,000Market Cap$185.20 million OptionableNot Optionable Beta1.25 Key ExecutivesBrendan DelaneyPresident & Chief Executive OfficerScott M. GiacobelloTreasurer, Chief Financial & Accounting OfficerBerta GrigorianVice President-Clinical OperationsLoretta M. ItriChief Medical OfficerAndrew KwonSenior Director-Business Development & StrategyKey CompetitorsKamadaNASDAQ:KMDAVera TherapeuticsNASDAQ:VERAAstria TherapeuticsNASDAQ:ATXSAC ImmuneNASDAQ:ACIUZevra TherapeuticsNASDAQ:KMPHView All CompetitorsInstitutional OwnershipSchonfeld Strategic Advisors LLCSold 56,200 shares on 2/15/2023Ownership: 0.087%Alps Advisors Inc.Bought 5,033 shares on 2/15/2023Ownership: 0.068%Annandale Capital LLCBought 10,000 shares on 2/15/2023Ownership: 0.041%MetLife Investment Management LLCBought 7,671 shares on 2/15/2023Ownership: 0.031%Morgan StanleySold 6,313 shares on 2/15/2023Ownership: 0.011%View All Institutional Transactions AADI Stock - Frequently Asked Questions Should I buy or sell Aadi Bioscience stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AADI shares. View AADI analyst ratings or view top-rated stocks. What is Aadi Bioscience's stock price forecast for 2023? 1 equities research analysts have issued 12-month price objectives for Aadi Bioscience's stock. Their AADI share price forecasts range from $30.00 to $48.00. On average, they anticipate the company's stock price to reach $41.67 in the next year. This suggests a possible upside of 449.0% from the stock's current price. View analysts price targets for AADI or view top-rated stocks among Wall Street analysts. How have AADI shares performed in 2023? Aadi Bioscience's stock was trading at $12.83 on January 1st, 2023. Since then, AADI shares have decreased by 40.8% and is now trading at $7.59. View the best growth stocks for 2023 here. Are investors shorting Aadi Bioscience? Aadi Bioscience saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,180,000 shares, an increase of 6.3% from the February 13th total of 1,110,000 shares. Based on an average daily trading volume, of 104,500 shares, the short-interest ratio is currently 11.3 days. Currently, 7.3% of the company's stock are short sold. View Aadi Bioscience's Short Interest. When is Aadi Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023. View our AADI earnings forecast. How can I listen to Aadi Bioscience's earnings call? Aadi Bioscience will be holding an earnings conference call on Tuesday, March 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Aadi Bioscience's earnings last quarter? Aadi Bioscience, Inc. (NASDAQ:AADI) released its earnings results on Tuesday, August, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.00) by $2.33. Aadi Bioscience had a negative net margin of 569.57% and a negative trailing twelve-month return on equity of 44.28%. What ETF holds Aadi Bioscience's stock ? ALPS Medical Breakthroughs ETF holds 16,567 shares of AADI stock, representing 0.13% of its portfolio. When did Aadi Bioscience's stock split? Aadi Bioscience shares reverse split on Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Aadi Bioscience's stock symbol? Aadi Bioscience trades on the NASDAQ under the ticker symbol "AADI." Who are Aadi Bioscience's major shareholders? Aadi Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (6.68%), Geode Capital Management LLC (1.07%), Opaleye Management Inc. (1.03%), Renaissance Technologies LLC (1.03%), Price T Rowe Associates Inc. MD (1.01%) and ExodusPoint Capital Management LP (0.31%). Insiders that own company stock include Caley Castelein, Neil Desai and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of Aadi Bioscience? Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aadi Bioscience's stock price today? One share of AADI stock can currently be purchased for approximately $7.59. How much money does Aadi Bioscience make? Aadi Bioscience (NASDAQ:AADI) has a market capitalization of $185.20 million and generates $1.12 million in revenue each year. The company earns $-110,090,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. How can I contact Aadi Bioscience? Aadi Bioscience's mailing address is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. The official website for the company is aadibio.com. The company can be reached via phone at (424) 473-8055 or via email at ikoffler@lifesciadvisors.com. This page (NASDAQ:AADI) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.